PRESS RELEASE published on 11/19/2025 at 08:41, 11 months 26 days ago Rapport Financier Semestriel 2025
PRESS RELEASE published on 11/18/2025 at 12:52, 11 months 27 days ago Rapport Financier Semestriel 2025
BRIEF published on 11/14/2025 at 23:10, 1 year ago MaaT Pharma : levée de fonds réussie de 9,1 millions d'euros Biotechnologie Innovation Médicale Investisseurs Microbiome Levée De Fonds
BRIEF published on 11/14/2025 at 23:10, 1 year ago MaaT Pharma: successful fundraising of 9.1 million euros Investors Biotechnology Fundraising Microbiome Medical Innovation
PRESS RELEASE published on 11/14/2025 at 23:05, 1 year ago Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...) MaaT Pharma annonce le succès de son Offre Globale de 9,1 millions d'euros pour le développement de Microbiome Ecosystem Therapies™. Levée de fonds pour Xervyteg® et MaaT033 Microbiome Ecosystem Therapies Offre Globale MaaT Pharma MaaT033 Xervyteg
PRESS RELEASE published on 11/14/2025 at 23:05, 1 year ago Inside Information / Operations of the issuer (acquisitions, sales...) MaaT Pharma successfully completes Global Offering of €9.1 million, strengthening financial position and supporting development of Microbiome Therapies for cancer patients Financial Position Global Offering MaaT Pharma Cancer Patients Microbiome Therapies
BRIEF published on 11/13/2025 at 19:45, 1 year ago Lancement d'une augmentation de capital par MaaT Pharma Augmentation De Capital Investisseurs Qualifiés Offre Globale MaaT Pharma Xervyteg® Commercialisation
BRIEF published on 11/13/2025 at 19:45, 1 year ago MaaT Pharma launches a capital increase Capital Increase Qualified Investors MaaT Pharma Global Offer Xervyteg® Marketing
PRESS RELEASE published on 11/13/2025 at 19:40, 1 year ago Informations privilégiées / Autres communiqués MaaT Pharma lance une augmentation de capital de 9 millions d'euros pour financer son développement. Offre d'actions nouvelles aux investisseurs. Projets de développement clinique et commercialisation Développement Augmentation De Capital Commercialisation Actions Nouvelles MaaT Pharma
Published on 11/14/2026 at 12:56, 1 day ago Gabriel Announces Dismissal of ICSID Annulment Application
Published on 11/14/2026 at 01:30, 1 day 11 hours ago NuRAN Wireless Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Published on 11/14/2026 at 00:40, 1 day 12 hours ago BEACN Announces Annual General and Special Meeting Results
Published on 11/14/2026 at 00:35, 1 day 12 hours ago American Hotel Income Properties REIT LP Reports Q3 2026 Results
Published on 11/14/2026 at 00:00, 1 day 13 hours ago SLAM Announces Proposed Extension of Warrant Expiry Dates
Published on 11/13/2026 at 23:24, 1 day 13 hours ago EQS-Adhoc: ASOS PLC: Repurchase of £90m of 2028 Convertible Bonds
Published on 11/13/2026 at 21:52, 1 day 15 hours ago EQS-Adhoc: Airbus reports share buyback transactions 9-13 November 2026
Published on 11/13/2026 at 19:08, 1 day 17 hours ago EQS-Adhoc: CHAPTERS Group AG: Successful Completion of Private Placement of the Capital Increase from Authorized Capital Resolved on November 13, 2026
Published on 11/13/2026 at 19:00, 1 day 18 hours ago Assemblée générale ordinaire des actionnaires le 18 décembre 2026
Published on 11/13/2026 at 11:35, 2 days 1 hour ago ENGIE and Google to partner on energy solutions for a potential data center project near Châteauroux, France
Published on 11/13/2026 at 11:35, 2 days 1 hour ago ENGIE et Google s’associent pour développer les solutions énergétiques d’un projet de data center envisagé près de Châteauroux, en France
Published on 11/13/2026 at 08:00, 2 days 5 hours ago Résultats trimestriels au 30 septembre 2026 - ANR par action : 101,54 €, en progression de + 7,8 % sur 9 mois - Capitaux propres consolidés : 772 M€
Published on 11/12/2026 at 23:12, 2 days 13 hours ago Belgrano continues the implementation of its public share buyback offer (OPRA)
